Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Katja Weisel, MD, George F. Geils, MD, Lionel Karlin, MD, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Tae-Hoon Chung, Chang-Ki Min, MD PhD, Kazutaka Sunami, MD PhD, Amanda Goldrick, MD, Belle Fang, Jessica Fowler, PhD, Maria-Victoria Mateos, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-133908

Published: 2020

Journal Articles

Effects of Delayed Treatment on Patients with Acute Myeloid Leukemia; Treatment Delay Matters in Younger Patients

Daehun Kwag, MD, Byung Sik Cho, MD, PhD, Gi June Min, MD, Sung-Soo Park, Silvia Park, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD PhD, Ki-Seong Eom, MD, PhD, Yoo-Jin Kim, MD, PhD, Seok Lee, MD, PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD, PhD, Dong-Wook Kim, MD, Jong Wook Lee, MD, PhD, Hee-Je Kim, MD PhD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143361

Published: 2020

Journal Articles

Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial

Sara Bringhen, MD, Luděk Pour, MD, Reuben Benjamin, MBBS, FRCPath, PhD, Sebastian Grosicki, MD PhD, Chang-Ki Min, MD PhD, Danielle Leao Cordeiro De Farias, MDMSc,MBA, Alexander Vorog, MD, Richard J Labotka, MD, Bingxia Wang, PhD, Dasha Cherepanov, Lauren E. Cain, MHS, ScM, PhD, Sudhakar Manne, S. Vincent Rajkumar, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136293

Published: 2020

Journal Articles

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136150

Published: 2020

Journal Articles

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

Kihyun Kim, MD PhD, Jin Seok Kim, MD PhD, Sung-Soo Yoon, MD PhD, Dok-Hyun Yoon, MD PhD, HyeonSeok Eom, MD PhD, Je-Jung Lee, MD PhD, Hyeonwoo Yim, MD PhD, Misun Park, MS, Hojoon Lee, DRPH,MDMPH,PhD, Chang Ki Min, MD PhD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136242

Published: 2020

Journal Articles

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Kim Huynh, BBiomedSc (Hons), PhD, Naomi Aoki, MSc, BSc, Kihyun Kim, MD PhD, Wee Joo Chng, MD PhD, Gin Gin Gan, MBBS, MRCP, FRCP, Chang-Ki Min, MD PhD, Je-Jung Lee, MD PhD, Yeow Tee Goh, MBBS, Cameron Wellard, Zoe McQuilten, MBBS, PhD, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136896

Published: 2020

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

Marcelo Capra, MD PhD, Thomas Martin, III, MD, Philippe Moreau, MD, Ross Baker, MBBS, FRACP, FRCPA, BSc, Ludek Pour, MD, Chang-Ki Min, MD PhD, Xavier Leleu, MD, Mohamad Mohty, MD PhD, Marta Reinoso Segura, Mehmet Turgut, MD, Richard Leblanc, MD FRCPC, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136415

Published: 2020

Journal Articles

A Phase 3 Trial of Thymoglobuline for Prevention of Chronic Gvhd in Transplantation from an HLA-Matched Sibling

Gi June Min, MD, Byung Sik Cho, MD, PhD, Sung-Soo Park, MD, PhD, Silvia Park, MD PhD, Seung-Ah Yahng, MD, PhD, Young-Woo Jeon, MD PhD, Seung-Hwan Shin, MD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD PhD, Ki-Seong Eom, MD, PhD, Yoo-Jin Kim, MD, PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD, PhD, Dong-Wook Kim, MD, Jong Wook Lee, MD, PhD, Heeje Kim, MD PhD, Seok Lee, MD, PhD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-139234

Published: 2020

Journal Articles

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Fredrik H. Schjesvold, MD PhD, Paul G. Richardson, MD, Michel Attal, MD PhD, Thierry Facon, MD, Adrián Alegre, MD, Andrew Spencer, DM, Artur Jurczyszyn, MD, Kazutaka Sunami, MD PhD, Laurent Frenzel, MD PhD, Chang-Ki Min, MD PhD, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Samira Bensfia, MD, Sara Bringhen

Blood (2019) 134 (Supplement_1): 1893.

https://doi.org/10.1182/blood-2019-128010

Published: 2019

Journal Articles

A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM)

Chang Ki Min, MD PhD, Kihyun Kim, MD PhD, Seok Jin Kim, MD PhD, Dok Hyun Yoon, Sung-Soo Park, Seunghoon Han, MD PhD

Blood (2019) 134 (Supplement_1): 1847.

https://doi.org/10.1182/blood-2019-127643

Published: 2019

Journal Articles

Comparison of Myeloablative (CyTBI, BuCy) Versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Low WT1 Expression Level at Transplant

Silvia Park, GI June MIN, MD, Sung-Soo Park, Seung-Ah Yahng, MD PhD, Young-Woo Jeon, MD PhD, Seung-Hwan Shin, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD, Byung-Sik Cho, MD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Dong-Wook Kim, Jong-Wook Lee, MD PhD, Hee-Je Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1973.

https://doi.org/10.1182/blood-2019-128306

Published: 2019

Journal Articles

Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study

Blood (2019) 134 (Supplement_1): 3066.

https://doi.org/10.1182/blood-2019-126867

Published: 2019

Journal Articles

Natural-Killer Cell Cytotoxicity Is a Diagnostic and Prognostic Marker in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Results from a Prospective Phase II Observational Study

Han Bi Lee, Jae-Ho Yoon, MD PhD, Gi June Min, MD, Sung-Soo Park, Silvia Park, Sung-Eun Lee, MD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Hee-Je Kim, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Jong Wook Lee, MD PhD

Blood (2019) 134 (Supplement_1): 2331.

https://doi.org/10.1182/blood-2019-129676

Published: 2019

Journal Articles

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Ji Hyun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Ho-Sup Lee, MD PhD, Sung-Soo Yoon, MD PhD, Dong-Yeop Shin, MD PhD, Ja Min Byun, Je-Jung Lee, MD PhD, Sung-Hoon Jung, MD, Chang-Ki Min, MD PhD, Hyo Jung Kim, MD PhD, Byeong Seok Sohn, MD PhD, Sung Hwa Bae, MD, Lee Gyeong-Won, Sungwoo Park, MD, Young Rok Do, PhDMD, Hyun Jung Lee, MD, Min Kyoung Kim, Yoo Jin Lee, MD PhD

Blood (2019) 134 (Supplement_1): 4372.

https://doi.org/10.1182/blood-2019-127707

Published: 2019

Journal Articles

Physical and Psychological Impairments As Practical Frailty Markers in Elderly AML Fit for Intensive Chemotherapy; Interim Data of a Prospective Cohort Study

GI June MIN, MD, Byung Sik Cho, MD PhD, Sung-Soo Park, MD, Silvia Park, Young-Woo Jeon, MD PhD, Seung-Hwan Shin, MD PhD, Seung-Ah Yahng, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Seok-Goo Cho, MD PhD, Chang-Ki Min, MD PhD, Dong-Wook Kim, Jong-Wook Lee, MD PhD, Hee-Je Kim, MD PhD

Blood (2019) 134 (Supplement_1): 3831.

https://doi.org/10.1182/blood-2019-123584

Published: 2019

Journal Articles

Poor Outcomes of HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation and High Ferritin Levels after a Reduced-Intensity Conditioning Regimen in Patients with Advanced Myelofibrosis

Han Bi Lee, Jae-Ho Yoon, MD PhD, Gi June Min, MD, Sung-Soo Park, Silvia Park, Sung-Eun Lee, MD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Hee-Je Kim, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Jong Wook Lee, MD PhD, Ki-Seong Eom, MD PhD

Blood (2019) 134 (Supplement_1): 5742.

https://doi.org/10.1182/blood-2019-130338

Published: 2019

Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Katja C. Weisel, MD, Pieter Sonneveld, Maria-Victoria Mateos, Vania T.M. Hungria, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Maria Krevvata, PhD, Sonali Trivedi, Xiang Qin, Huiling Pei, PhD, Jon Ukropec, PhD, Rachel Kobos, MD, Ming Qi, MD PhD, Ajay K Nooka, MDMPH

Blood (2019) 134 (Supplement_1): 3192.

https://doi.org/10.1182/blood-2019-123527

Published: 2019

Journal Articles

Genetic Characteristics and Clinical Outcomes of T-Cell Acute Lymphoblastic Leukemia; Myeloid-Suppressive Therapeutic Approach Based on Allogeneic Hematopoietic Cell Transplantation May Benefit in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Jae-Ho Yoon, MD PhD, Han Bi Lee, Gi June Min, MD, Sung-Soo Park, Silvia Park, Byung Sik Cho, MD PhD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Hee-Je Kim, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Jong Wook Lee, MD PhD, Seok Lee, MD PhD

Blood (2019) 134 (Supplement_1): 1470.

https://doi.org/10.1182/blood-2019-129870

Published: 2019

Journal Articles

Comparable Outcomes between Unrelated Donor (8/8 or 7/8 matched) and Haploidentical Donor for Allogeneic Stem Cell Transplantation in Adult Patients with Severe Aplastic Anemia

Jee Yon Shin, Sung-Soo Park, Gi June Min, MD, Silvia Park, Sung-Eun Lee, MD, Jae-Ho Yoon, MD PhD, Seung-Hwan Shin, MD PhD, Sung-Eun Lee, MD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang-Ki Min, MD PhD, Hee-Je Kim, MD PhD, Seok-Goo Cho, MD PhD, Jong-Wook Lee, MD

Blood (2019) 134 (Supplement_1): 4619.

https://doi.org/10.1182/blood-2019-130419

Published: 2019

Journal Articles

Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Gi June Min, MD, Hee-Je Kim, MD PhD, Sung-Soo Park, MD, Silvia Park, Young-Woo Jeon, MD PhD, Seung-Ah Yahng, MD PhD, Seung-Hwan Shin, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD, Byung Sik Cho, MD PhD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Dong-Wook Kim, Jong-Wook Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3260.

https://doi.org/10.1182/blood-2019-124275

Published: 2019

NARROW

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Effects of Delayed Treatment on Patients with Acute Myeloid Leukemia; Treatment Delay Matters in Younger Patients

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

A Phase 3 Trial of Thymoglobuline for Prevention of Chronic Gvhd in Transplantation from an HLA-Matched Sibling

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM)

Comparison of Myeloablative (CyTBI, BuCy) Versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Low WT1 Expression Level at Transplant

Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study

Natural-Killer Cell Cytotoxicity Is a Diagnostic and Prognostic Marker in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Results from a Prospective Phase II Observational Study

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Physical and Psychological Impairments As Practical Frailty Markers in Elderly AML Fit for Intensive Chemotherapy; Interim Data of a Prospective Cohort Study

Poor Outcomes of HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation and High Ferritin Levels after a Reduced-Intensity Conditioning Regimen in Patients with Advanced Myelofibrosis

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Genetic Characteristics and Clinical Outcomes of T-Cell Acute Lymphoblastic Leukemia; Myeloid-Suppressive Therapeutic Approach Based on Allogeneic Hematopoietic Cell Transplantation May Benefit in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Comparable Outcomes between Unrelated Donor (8/8 or 7/8 matched) and Haploidentical Donor for Allogeneic Stem Cell Transplantation in Adult Patients with Severe Aplastic Anemia

Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only